Anebulo Pharmaceuticals, Inc.

NasdaqCM ANEB

Anebulo Pharmaceuticals, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.00

Anebulo Pharmaceuticals, Inc. Revenue Per Share is USD 0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Anebulo Pharmaceuticals, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 0.00, a 0.00% change year over year.
Anebulo Pharmaceuticals, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 0.00, a 0.00% change year over year.
Anebulo Pharmaceuticals, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 0.00.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

NasdaqCM: ANEB

Anebulo Pharmaceuticals, Inc.

CEO	Mr. Richard Anthony Cunningham
IPO Date	May 7, 2021
Location	United States
Headquarters	1415 Ranch Road 620 South
Employees	2
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Key trends

Past 5 years